Kewaunee Reports Q3 Revenue of $69.4M, Successfully Acquires Nu Aire
Reports Q3 revenue $69.4M vs. $67.47M last year. "Following the successful turnaround of the business, we embarked on a strategy that accelerated inorganic growth, which led to the successful completion of the Company's acquisition of Nu Aire," said CEO Thomas Hull III. "Since then, our teams have worked diligently to integrate Nu Aire into the Kewaunee family and position the business for meaningful growth and EBITDA contribution. We have also continued to invest in our corporate platform to support the next phase of our inorganic growth strategy. These investments include strengthening our corporate team, implementing a robust financial consolidation system, and enhancing our readiness to comply with the SEC's accelerated reporting requirements. As is traditionally the case," Hull continued, "our third quarter results often represent our softest quarter due to the impact of the holiday schedule in the United States, a general slowdown of construction schedules in the winter months, and customers looking to wrap up any construction projects before the calendar year-end. This trend was further exacerbated by significant geopolitical and economic uncertainty, and by the volatility in project delivery timelines that we have previously discussed. Although the construction-related portion of our business has been soft this fiscal year, the addition of Nu Aire's end-user containment products has helped offset that softness..."
Trade with 70% Backtested Accuracy
Analyst Views on KEQU
About KEQU
About the author

- Profit Decline: Kewaunee Scientific Corporation reported a fourth-quarter net profit of $3.39 million, or $1.13 per share, which represents a significant drop from last year's $4.85 million and $1.63 per share, indicating a weakening in the company's profitability.
- Adjusted Earnings: Excluding special items, the company reported adjusted earnings of $3.40 million, or $1.14 per share, which, while slightly higher than GAAP figures, still reflects overall profitability challenges.
- Revenue Drop: The company's fourth-quarter revenue fell to $71.40 million, a 7.5% decrease from $77.15 million last year, suggesting potential impacts on market demand that warrant attention for future sales strategies.
- Market Reaction: The dual decline in profit and revenue has led to a cautious market outlook for Kewaunee Scientific, which may affect its stock performance and investor confidence moving forward.
- Significant Sales Growth: Kewaunee Scientific reported sales of $281.99 million for FY 2026, a 17.3% increase, demonstrating the company's ability to achieve robust growth post-Nu Aire integration despite market challenges, enhancing its competitive position.
- Profitability Fluctuations: Net earnings for FY 2026 were $9.62 million, down 15.7% from the previous year, reflecting pressures from high costs and project delivery timeline volatility, indicating a need for improved cost controls to maintain profitability.
- Strong International Performance: International sales reached $67.11 million, a 9.9% increase, showcasing the resilience of the international team in navigating geopolitical uncertainties through effective project execution and management, supporting future growth potential.
- Balance Sheet Improvement: The company successfully reduced long-term debt by approximately $20 million, improving its debt-to-equity ratio from 0.99 to 0.61, indicating enhanced financial health and laying the groundwork for future acquisitions and expansion.
- Significant Sales Growth: Kewaunee achieved sales of $281.99 million in fiscal year 2026, representing a 17.3% increase compared to the previous year, indicating strong market demand post-Nu Aire integration and enhancing its position in the laboratory products sector.
- Profitability Fluctuations: Despite the sales growth, net earnings for fiscal year 2026 were $9.62 million, down 15.5% from $11.41 million the previous year, reflecting profitability pressures amid high costs and market volatility, necessitating further cost optimization to maintain margins.
- Strong International Performance: International sales reached $67.11 million, a 9.9% increase, demonstrating the company's resilience in the global market and robust project backlog despite heightened geopolitical uncertainties, bolstering confidence in future growth prospects.
- Improved Balance Sheet: The company successfully reduced long-term debt by approximately $20 million in fiscal year 2026, improving its debt-to-equity ratio from 0.99 to 0.61, indicating significant progress in financial health and laying a solid foundation for future expansion and acquisitions.
- Earnings Highlights: Kewaunee Scientific reported a Q4 GAAP EPS of $1.13, with revenue of $71.4 million reflecting a 7.5% year-over-year decline, indicating resilience amid market challenges.
- Annual Sales Growth: The company achieved $281.99 million in sales for fiscal year 2026, representing a 17.3% increase from $240.47 million in the previous year, showcasing positive performance in product demand and market share.
- Profitability Changes: Pre-tax earnings for the fiscal year were $13.73 million, down from $14.79 million the prior year, while net earnings decreased from $11.41 million to $9.62 million, reflecting the impact of cost pressures on profitability.
- Decline in EPS: Diluted earnings per share fell to $3.22 from $3.83 in the previous fiscal year, indicating challenges in profitability that may affect investor confidence.
- Earnings Release Plan: Kewaunee Scientific Corporation plans to release its fourth quarter and fiscal year 2026 financial results on June 23, 2026, after market close, which is expected to provide investors with crucial performance data and future outlook.
- Company Background: Founded in 1906, Kewaunee is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, including steel and wood casework, fume hoods, and biological safety cabinets, showcasing its strong industry presence.
- Acquisition Details: The recently acquired subsidiary, Nu Aire, specializes in manufacturing biological safety cabinets and ultralow freezers, which complements Kewaunee's product portfolio and enhances its competitive edge in the market.
- Global Operations: Kewaunee operates multiple sales and manufacturing facilities across the U.S., India, and other countries, demonstrating its extensive international footprint and capability to serve global customers.
- Earnings Performance: Kewaunee Scientific reported a Q3 GAAP EPS of $0.23, indicating stability in profitability despite facing market challenges.
- Revenue Growth: The company achieved revenues of $69.4 million in Q3, reflecting a year-over-year increase of 3.3%, showcasing sustained demand in the laboratory equipment market and an expanding customer base.
- Market Performance Analysis: Although the revenue growth rate is modest, the stable profitability and slight increase suggest that the company maintains a solid competitive position in the industry, potentially attracting more investor interest.
- Future Outlook: Kewaunee Scientific's financial performance lays a foundation for future growth, and management may leverage this positive trend to drive new product development and market expansion strategies.









